Please provide your email address to receive an email when new articles are posted on . FORT WORTH, Texas — An aspheric IOL has been recognized as belonging to the subset of new technology IOLs that ...
TORONTO, Nov. 17, 2020 /CNW/ - Alcon, the global leader in eye care, is pleased to announce the Canadian launch of AcrySof ® IQ Vivity ®, a first-of-its-kind, surgical lens designed to help cataract ...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, has commercially launched the first and only non-diffractive extended depth ...
PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
The unique optical design of the ACTIVEFOCUS (TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses The ...
Please provide your email address to receive an email when new articles are posted on . MILAN — Alcon announced the launch of the AcrySof IQ ReSTOR +2.5 D and the AcrySof IQ ReSTOR multifocal toric +2 ...
Disclaimer: This is sponsored content paid for by Vision for Life. All opinions and views are of the advertiser and does not reflect the same of NewsChannel 5 Nashville. In today’s Your Health Matters ...
(RTTNews) - Alcon, a division of Novartis, reported new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens compared to the ZEISS AT ...
FORT WORTH, Texas--(BUSINESS WIRE)--May 21, 2006--Alcon, Inc. (NYSE:ACL) announced today that the Centers for Medicare and Medicaid Services (CMS) recognized the AcrySof(R) IQ intraocular lens (IOL) ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...